Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology firm, will report its third-quarter financial results on November 7, 2022, after market close. The company is focused on developing therapies for RAS-addicted cancers, with RMC-6236 and RMC-6291 currently in clinical trials. Senior management will host a webcast at 4:30 p.m. ET on the same day to discuss the financial outcomes and corporate advancements, which will be accessible via their website for 14 days post-event.

Positive

• Focus on RAS-addicted cancers suggests potential for niche market growth.
• R&D pipeline includes multiple clinical-stage compounds, indicating robust development.

Negative

• Pending financial results may reflect uncertainty and volatility for RVMD shares.

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291 (KRAS^G12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS^G12D), currently in IND-enabling development, RMC-8839 (KRAS^G13C), and additional compounds targeting additional RAS variants. RAS Companion Inhibitors currently in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When will Revolution Medicines report its Q3 2022 financial results?

Revolution Medicines will report its Q3 2022 financial results on November 7, 2022, after market close.

What time will the webcast for financial results take place?

The webcast will take place at 4:30 p.m. Eastern Time on November 7, 2022.

What is the focus area of Revolution Medicines?

Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers.

What compounds are currently in Revolution Medicines' pipeline?

Currently, RMC-6236 and RMC-6291 are in clinical development, targeting various RAS oncogenic variants.

How long will the webcast replay be available?

The replay of the webcast will be available on the company's website for at least 14 days.